Biohaven Gets Pfizer’s Help To Make Nurtec An Ex-US Success Story Too

As the only oral CGRP migraine therapy approved for both prevention and acute therapy, Nurtec has taken significant US market share. Biohaven will call on Pfizer’s expertise and contacts to repeat that success abroad.

Diagnosis - Migraine. Medical Concept with Red Pills, Injections and Syringe. Selective Focus. 3D Render.
Biohaven enlists Pfizer's help in bring Nurtec to international markets

Pfizer Inc. joined the migraine market competition on 9 November via a deal bringing it ex-US commercial rights to Biohaven Pharmaceutical Holding Company Ltd.’s Nurtec ODT (rimegepant) as well as a follow-on oral calcitonin gene-related peptide (CGRP) inhibitor for $500m up front. With significant earnout potential, the agreement strengthens Biohaven financially, removes its financial risk for commercializing Nurtec overseas and gives it a commercial partner with broad access and experience outside the US.

[Sidebar#SC144877]

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

More from Deals

More from Business

  • How A New Healthcare Dialogue Is Driving Market Access In Mexico

    Companies stand a better chance of securing public reimbursement in Mexico for innovative medicines if they understand changing approaches to healthcare. The shift means the emergence of managed entry agreements and a focus on economic impact, explains AMIIF, Mexico's research-based pharmaceutical industry association.

  • How Novartis Is Elevating CVD Outcomes, Driving ‘Personalized Access’ In APMA

    Novartis’s APMA chief outlines the company’s tailored approach to deliver long-term outcomes, novel access solutions via innovative financing options and shape the CVD disease ecosystem in the extraordinarily diverse region. Partnering to build AI infrastructure is another key prong.

  • India Rare Diseases: Court Shows Path For Policy Action, Funding, Price Issues-- Test-2

    A court order encompassing funding, drug pricing, clinical trials and overall policy implementation aspects is expected to bring about a paradigm shift in the treatment of rare diseases in India. Sarepta, Roche and Sanofi are among the key players that have been part of pricing discussions.